Valuation: BioNTech SE

Capitalization 19.92B 23.24B 18.21B 17.35B 31.88B 2,226B 32.19B 217B 84.54B 1,059B 87.22B 85.35B 3,681B P/E ratio 2026 *
-17.8x
P/E ratio 2027 * -17.7x
Enterprise value 7.26B 8.47B 6.64B 6.32B 11.61B 811B 11.73B 79.19B 30.8B 386B 31.77B 31.09B 1,341B EV / Sales 2026 *
3.4x
EV / Sales 2027 * 4.07x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.26%
1 week-3.43%
Current month-11.08%
1 month-4.87%
3 months-13.11%
6 months-11.45%
Current year-3.37%
1 week 90.88
Extreme 90.88
96.8
1 month 90.79
Extreme 90.79
113.26
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-0.26%-3.43%-2.66%-12.59% 23.32B
+1.02%+0.84%+42.05%+87.52% 50.04B
-5.43%-5.50%+72.08%+55.56% 48.62B
-2.01%-15.66%+75.95%+517.30% 25.57B
-3.60%-1.03%+40.99%-29.12% 17.89B
-1.66%-4.83%+32.60%-41.30% 16.2B
-2.75%-7.27%+53.03%+190.95% 14.97B
-3.46%+1.62%-26.29%+954.65% 14.58B
-3.89%-5.40%+38.03% - 13.47B
-0.37%+4.93%+38.29%+166.42% 12.89B
Average -2.24%-1.86%+36.41%+209.93% 23.76B
Weighted average by Cap. -2.15%-2.47%+42.80%+168.47%

Financials

2026 *2027 *
Net sales 2.13B 2.49B 1.95B 1.86B 3.42B 239B 3.45B 23.29B 9.06B 114B 9.35B 9.15B 394B 2.21B 2.58B 2.02B 1.93B 3.54B 247B 3.58B 24.15B 9.39B 118B 9.69B 9.48B 409B
Net income -1.02B -1.19B -934M -889M -1.63B -114B -1.65B -11.14B -4.33B -54.31B -4.47B -4.38B -189B -1.2B -1.4B -1.09B -1.04B -1.92B -134B -1.93B -13.07B -5.08B -63.67B -5.24B -5.13B -221B
Net Debt -12.66B -14.78B -11.58B -11.03B -20.26B -1,415B -20.46B -138B -53.74B -673B -55.45B -54.26B -2,340B -10.92B -12.74B -9.98B -9.51B -17.47B -1,220B -17.64B -119B -46.34B -581B -47.81B -46.79B -2,018B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-05-14 91.99 $ -0.26% 638,980
26-05-13 92.23 $ -1.53% 879,930
26-05-12 93.66 $ +0.34% 384,822
26-05-11 93.34 $ -0.83% 647,776
26-05-08 94.12 $ +1.19% 1,035,633
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
78.76EUR
Average target price
109.47EUR
Spread / Average Target
+38.99%

Quarterly revenue - Rate of surprise